1
|
Cieslik PA, Klingler S, Nolff M, Holland JP. Radiolabelled 177 Lu-Bispidine-Trastuzumab for Targeting Human Epidermal Growth Factor Receptor 2 Positive Cancers. Chemistry 2024; 30:e202303805. [PMID: 38064536 DOI: 10.1002/chem.202303805] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2023] [Indexed: 01/18/2024]
Abstract
Radioimmunotherapy (RIT) is a promising alternative to conventional treatment options. Here, we present experimental work on the synthesis, radiochemistry, and in vivo performance of a lanthanoid-selective nonadentate bispidine ligand suitable for 177 Lu3+ ion complexation. The ligand (bisp,1) was derivatised with a photoactivatable aryl azide (ArN3 ) group as a bioconjugation handle for light-induced labelling of proteins. Quantitative radiosynthesis of [177 Lu]Lu-1+ was accomplished in 10 minutes at 40 °C. Subsequent incubation of [177 Lu]Lu-1+ with trastuzumab, followed by irradiation with light at 365 nm for 15 min, at room temperature and pH 8.0-8.3, gave the radiolabelled mAb, [177 Lu]Lu-1-azepin-trastuzumab ([177 Lu]Lu-1-mAb) in a decay-corrected radiochemical yield of 14 %, and radiochemical purity (RCP)>90 %. Stability studies and cellular binding assays in vitro using the SK-OV-3 human ovarian cancer cells confirmed that [177 Lu]Lu-1-mAb remained biological active and displayed specific binding to HER2/neu. Experiments in immunocompromised female athymic nude mice bearing subcutaneous xenograft models of SK-OV-3 tumours revealed significantly higher tumour uptake in the normal group compared with the control block group (29.8±11.4 %ID g-1 vs. 14.8±6.1 %ID g-1 , respectively; P-value=0.037). The data indicate that bispidine-based ligand systems are suitable starting points for constructing novel, high-denticity chelators for specific complexation of larger radiotheranostic metal ion nuclides.
Collapse
Affiliation(s)
- Patrick A Cieslik
- University of Zurich, Department of Chemistry, Winterthurerstrasse 190, CH-8057, Zurich, Switzerland
| | - Simon Klingler
- University of Zurich, Department of Chemistry, Winterthurerstrasse 190, CH-8057, Zurich, Switzerland
| | - Mirja Nolff
- Klinik für Kleintierchirurgie, Vetsuisse-Fakultät, University of Zurich, Wintherturerstrasse 260, CH-8057, Zurich, Switzerland
| | - Jason P Holland
- University of Zurich, Department of Chemistry, Winterthurerstrasse 190, CH-8057, Zurich, Switzerland
| |
Collapse
|
2
|
Favaretto C, Grundler PV, Talip Z, Köster U, Johnston K, Busslinger SD, Sprung P, Hillhouse CC, Eichler R, Schibli R, Müller C, van der Meulen NP. Terbium-149 production: a focus on yield and quality improvement towards preclinical application. Sci Rep 2024; 14:3284. [PMID: 38332245 PMCID: PMC10853284 DOI: 10.1038/s41598-024-53610-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2023] [Accepted: 02/02/2024] [Indexed: 02/10/2024] Open
Abstract
Terbium-149 (T1/2 = 4.1 h, Eα = 3.98 MeV (16.7%), 28 µm range in tissue) is a radionuclide with potential for targeted alpha therapy. Due to the negligible emission of α-emitting daughter nuclides, toxicity to healthy tissue may be reduced in comparison with other α-particle emitters. In this study, terbium-149 was produced via 1.4 GeV proton irradiation of a tantalum target at the CERN-ISOLDE facility. The spallation products were mass separated and implanted on zinc-coated foils and, later, radiochemically processed. Terbium-149 was separated from the co-produced isobaric radioisotopes and the zinc coating from the implantation foil, using cation-exchange and extraction chromatographic techniques, respectively. At the end of separation, up to 260 MBq terbium-149 were obtained with > 99% radionuclidic purity. Radiolabeling experiments were performed with DOTATATE, achieving 50 MBq/nmol apparent molar activity with radiochemical purity > 99%. The chemical purity was determined by inductively coupled plasma-mass spectrometry measurements, which showed lead, copper, iron and zinc only at ppb level. The radiolabeling of the somatostatin analogue DOTATATE with [149Tb]TbCl3 and the subsequent in vivo PET/CT scans conducted in xenografted mice, showing good tumor uptake, further demonstrated product quality and its ability to be used in a preclinical setting.
Collapse
Affiliation(s)
- C Favaretto
- Nuclear Medicine Department, University Hospital Basel, Basel, Switzerland
- Center for Radiopharmaceutical Sciences ETH-PSI, Paul Scherrer Institute, 5232, Villigen-PSI, Switzerland
| | - P V Grundler
- Center for Radiopharmaceutical Sciences ETH-PSI, Paul Scherrer Institute, 5232, Villigen-PSI, Switzerland
| | - Z Talip
- Center for Radiopharmaceutical Sciences ETH-PSI, Paul Scherrer Institute, 5232, Villigen-PSI, Switzerland
| | - U Köster
- Institute Laue-Langevin, Grenoble, France
- Physics Department, ISOLDE/CERN, Geneva, Switzerland
| | - K Johnston
- Physics Department, ISOLDE/CERN, Geneva, Switzerland
| | - S D Busslinger
- Center for Radiopharmaceutical Sciences ETH-PSI, Paul Scherrer Institute, 5232, Villigen-PSI, Switzerland
| | - P Sprung
- Department Hot Laboratory, Paul Scherrer Institute, Villigen-PSI, Switzerland
| | - C C Hillhouse
- Laboratory of Radiochemistry, Paul Scherrer Institute, Villigen-PSI, Switzerland
| | - R Eichler
- Laboratory of Radiochemistry, Paul Scherrer Institute, Villigen-PSI, Switzerland
- Department of Chemistry, Biochemistry and Pharmaceutical Sciences, University of Bern, Bern, Switzerland
| | - R Schibli
- Center for Radiopharmaceutical Sciences ETH-PSI, Paul Scherrer Institute, 5232, Villigen-PSI, Switzerland
- Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, Switzerland
| | - C Müller
- Center for Radiopharmaceutical Sciences ETH-PSI, Paul Scherrer Institute, 5232, Villigen-PSI, Switzerland
- Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, Switzerland
| | - N P van der Meulen
- Center for Radiopharmaceutical Sciences ETH-PSI, Paul Scherrer Institute, 5232, Villigen-PSI, Switzerland.
- Laboratory of Radiochemistry, Paul Scherrer Institute, Villigen-PSI, Switzerland.
| |
Collapse
|